Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Crystal form of compound, and preparation method thereof, composition, and applications of crystal form and composition

A technology of compounds and compositions, applied in the field of medicinal chemistry

Active Publication Date: 2018-01-19
WUHAN LL SCI & TECH DEV
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, there is still a need in the prior art to continue to develop more suitable forms of the above-mentioned compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form of compound, and preparation method thereof, composition, and applications of crystal form and composition
  • Crystal form of compound, and preparation method thereof, composition, and applications of crystal form and composition
  • Crystal form of compound, and preparation method thereof, composition, and applications of crystal form and composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Embodiment 1: the preparation of formula (A) compound

[0090] Dissolve the compound of formula (B) (1.0g) in dichloromethane (5ml), stir at room temperature to form a solution, add potassium phthalimide (0.27g) to the solution, keep the reaction for 4h, cool to -50 °C, filtered, and the solvent was spin-dried to obtain a solid that was the compound of formula (A) (amorphous).

[0091] Melting point: 135-145°C.

[0092] MS / HRMS m / z: 717[M+H] + ;677[M-K] - .

[0093] 1 H-NMR (400MHz, DMSO-d 6 )δ: 1.44(t, 3H), 1.46(t, 3H), 2.38(s, 3H), 2.41(s, 3H), 2.44(s, 3H), 4.64(q, 2H), 5.29(d, 1H ), 5.32(d, 1H), 5.52(d, 1H), 5.56(d, 1H), 6.86(q, 1H), 6.90(d, 2H), 7.18(m, 2H), 7.22(d, 2H) , 7.33 (m, 1H), 7.36 (m, 1H), 7.46 (d, 1H), 7.52 (dd, 1H), 7.75 (d, 1H).

[0094] 1 H-NMR spectrum and X-ray powder diffraction spectrum are shown in Figure 5 and Figure 6 .

Embodiment 2

[0095] Embodiment 2: Antihypertensive efficacy test of formula (A) compound on spontaneously hypertensive rats

[0096] Spontaneously hypertensive rats aged 12 weeks (hereinafter referred to as SHR, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were anesthetized by intraperitoneal injection of 2.5% sodium pentobarbital. The blood pressure sensing catheter was inserted into the abdominal aorta, the implant was fixed on the abdominal wall, and the postoperative daily care was performed after suturing. Animals whose systolic blood pressure exceeded 160mm Hg were selected into groups, with 8 animals in each group, 3 groups in total. The matched group is given 0.5% sodium carboxymethylcellulose (hereinafter referred to as CMC-Na); formula (B) compound group and formula (A) compound group adopt 0.5% CMC-Na to dissolve, and dosage is all at 1mg / kg A Zisartan effective dose meter, the administration volume is 4mL / kg, all are administered by intragastr...

Embodiment 3

[0107] Embodiment 3: the preparation of crystal form I

[0108] (1) Take 15 mg of the compound of formula (A), add 0.2 ml of ethanol / isopropyl ether (volume ratio 1:5) mixed solution to obtain a suspension, stir at room temperature for 1 day, filter, and dry to obtain crystal form I. See the attached XRD detection pattern figure 1 ; DSC: 184°C. According to the same method, use ethanol / n-heptane (volume ratio of 1:5) mixed solution, isopropanol / n-heptane (volume ratio of 1:5) mixed solution, or tetrahydrofuran / n-heptane (volume ratio of 1:5) mixed solution was also prepared to obtain the crystal form I.

[0109] (2) Dissolve 15 mg of the compound of formula (A) in 0.1 ml of methanol to obtain a clear solution, add 1.0 ml of isopropyl ether under stirring, and precipitate a solid, continue stirring, filter, and dry to obtain crystal form I. In the same way, use good solvent ethanol / antisolvent isopropyl ether, good solvent ethanol / antisolvent methyl tert-butyl ether, good so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to View More

Abstract

The present invention provides a crystal form represented by a formula (A) of a compound, and a preparation method thereof, a composition, and applications of the crystal form and the composition in preparation of angiotensin II receptor antagonists, or in preparation of drugs for prevention and / or treatment of hypertension, chronic heart failure, and diabetic nephropathy. The formula (A) is defined in the specification.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a crystal form of a compound and a preparation method, composition and application thereof. Background technique [0002] Hypertension (Hypertension) is the most common cardiovascular disease, and it is also a major risk factor leading to increased morbidity and mortality of congestive heart failure, stroke, coronary heart disease, renal failure, and aortic aneurysm. Antihypertensive drugs play a key role in the treatment and prevention of hypertension. With the deepening understanding of the pathogenesis of hypertension, many antihypertensive drugs with better efficacy, such as diuretics, β-blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors (ACEI, Puryl class), angiotensin II AT1 receptor antagonists (ARB, sartan class), have been discovered and successfully applied clinically. After years of clinical practice, it has been confirmed that the AT1 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D413/14A61K31/497A61P9/12A61P9/04A61P3/10A61P13/12
CPCA61K31/4245A61P9/06A61P9/00A61P9/12C07D413/14A61P13/12A61P9/04C07B2200/13
Inventor 雷四军方祥陈永凯冯伟王朝东
Owner WUHAN LL SCI & TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com